TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30886131
Drug: Transversalis fascia
Normalized name: OCTINOXATE .012 mL in 6 mL / OCTISALATE .12 mL in 6 mL TOPICAL CREAM [RIMMEL LONDON MOISTURE RENEW LIPGLOSS - FUSCIA THERAPHY (345)]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transversalis fascia plane (TFP) block with 20 ml of 0.5% ropivacaine
Study: 28796053
Drug: 14-day berberine-containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14-day berberine-containing quadruple therapy
Study: 23174856
Drug: Nitrate-rich concentrated
Normalized name: Nitrate
DrugBank: Nitrate (DB14049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrate-rich concentrated beetroot juice (BR; 2 × 70 ml/day, ∼9.6 mmol/day NO(3)(‐))
Study: 23174856
Drug: Nitrate-depleted beetroot
Normalized name: Nitrate
DrugBank: Nitrate (DB14049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrate-depleted beetroot juice placebo (PL; 2 × 70 ml/day, ∼0.01 mmol/day NO(3)(‐))
Study: 21774637
Drug: Preparation without
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation without teaching
Study: 21774637
Drug: Teaching vs
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teaching vs Preparation
Study: 21774637
Drug: Teaching vs
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teaching vs Preparation (60 days later)
Study: 15753134
Drug: High-fat meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fat meal (17.5 g fat)
Study: 15753134
Drug: Low-fat meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fat meal (2.7 g fat)
Study: 15753134
Drug: High-fat toast
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fat toast and butter (17.5 g fat)
Study: 15753134
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E supplementation (400 mg/day, 4 weeks)
Study: 7742830
Drug: Oral theophylline
Normalized name: theophylline Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral theophylline (350 mg b.i.d.)
Study: 2330167
Drug: Vacu‐Cut needle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vacu‐Cut needle (19.5 G)
Study: 2330167
Drug: Menghini needle
Normalized name: NEEDLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Menghini needle (17 G)
Study: 7016124
Drug: Praziquantel (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Praziquantel (1 x 30 mg/kg, 1 x 40 mg/kg, 2 x 20 mg/kg)
Study: 7016124
Drug: Placebo (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1 x 40 mg/kg)
Study: 15385359
Drug: Isoflurane inhalation
Normalized name: isoflurane INHALATION GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoflurane inhalation combined with positive pressure ventilation (PPV)
Study: 11496849
Drug: Antiarrhythmic-drug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiarrhythmic-drug therapy
Study: 7913326
Drug: Zidovudine 500
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zidovudine 500 mg twice daily for 104 weeks (initially 250 mg four times daily for the first 4 weeks)
Study: 7913326
Drug: Placebo twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo twice daily for 104 weeks
Study: 30169323
Drug: Late parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late parenteral nutrition (withholding for 1 week)
Study: 30169323
Drug: Early parenteral
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early parenteral nutrition (initiated within 24 h)
Study: 22928590
Drug: BIS biosignal
Normalized name: bis-ethoxydiglycol succinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIS biosignal with 0.6 mg/kg rocuronium
Study: 22928590
Drug: BIS biosignal
Normalized name: bis-ethoxydiglycol succinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIS biosignal with 1.2 mg/kg rocuronium
Study: 22928590
Drug: Entropy biosignal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entropy biosignal with 0.6 mg/kg rocuronium
Study: 22928590
Drug: Entropy biosignal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entropy biosignal with 1.2 mg/kg rocuronium
Study: 21115455
Drug: Vancomycin plus
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vancomycin plus aztreonam 1 g every 12 h for 5-14 days
Study: 17976094
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium (4 grams)
Study: 17976094
Drug: Intravenous ibutilide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ibutilide without magnesium
Study: 17976094
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium (1 to 3 grams)
Study: 17976094
Drug: No adjunctive
Approvals — FDA: no, EMA: no, PMDA: no
Description: No adjunctive magnesium
Study: 8186350
Drug: Pantoprazole 40
Normalized name: pantoprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole 40 mg at breakfast
Study: 3285638
Drug: 0.6 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 mg/kg dexamethasone
Study: 24026991
Drug: Low level
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low level laser therapy (LLLT) with wavelength of 78 nm and 2.5 j/cm2, two times a week for 5 min, for one month
Study: 19359232
Drug: Intrathecal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal therapy with 1 500 IU of antitetanus serum and 1.5 g of intravenous metronidazole daily
Study: 19359232
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment of 9 000 IU of antitetanus serum (4 500 IU cutaneously and 4 500 IU intramuscularly)
Study: 16176204
Drug: Repaglinide (2-9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repaglinide (2-9 mg/day, average 5.9 mg)
Study: 16176204
Drug: Repaglinide (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repaglinide (0.5 mg acute exposure)
Study: 1354276
Drug: Ribose 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribose 60 g daily in four doses by mouth for 3 days
Study: 30280657
Drug: Brigatinib (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brigatinib (180 mg once daily with a 7-day lead-in period at 90 mg)
Study: 25188501
Drug: AOM 400
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AOM 400 mg
Study: 22640674
Drug: Mini-implant system
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mini-implant system
Study: 17957155
Drug: Probiotic formula
Normalized name: Probiotic Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic formula (LGG and Bifidobacterium longum) administered during the first 6 months of life
Study: 17957155
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no probiotic administration)
Study: 15586515
Drug: 0.25% bupivicaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25% bupivicaine via elastomeric infusion pump (ON-Q) for 48 hours at 2 cc/h
Study: 15586515
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution via elastomeric infusion pump (ON-Q) for 48 hours at 2 cc/h
Study: 3340474
Drug: Simultaneous administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simultaneous administration of MMR, DTP, and OPV vaccines
Study: 3340474
Drug: Sequential administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sequential administration of MMR followed by booster doses of DTP and OPV 2 months later
Study: 28599629
Drug: Methoxamine 4
Normalized name: methoxamine
DrugBank: Methoxamine (DB00723)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methoxamine 4 μg·kg‐1·min‐1 (M3)
Study: 28599629
Drug: Methoxamine 2
Normalized name: methoxamine 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methoxamine 2 μg·kg‐1·min‐1 (M1)
Study: 28599629
Drug: Methoxamine 3
Normalized name: methoxamine
DrugBank: Methoxamine (DB00723)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methoxamine 3 μg·kg‐1·min‐1 (M2)
Study: 24589564
Drug: Subcutaneous abdominal
Normalized name: PAD,ABDOMINAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous abdominal adipose tissue (SAT)
Study: 19536915
Drug: Additional 12-week
Normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Additional 12-week treatment with varenicline
Study: 15273395
Drug: Synthetic conjugate
Normalized name: synthetic conjugated estrogens, A
DrugBank: Synthetic Conjugated Estrogens, A (DB09317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic conjugate polysaccharide vaccine against Hib
Study: 10223783
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg BMS‐186716
Study: 7872185
Drug: Enoxaparin (combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (combined 40 mg and 60 mg)
Study: 359019
Drug: Tienylic acid
Normalized name: 3-(3-methyl-2-thienyl)acrylic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tienylic acid (500 mg)
Study: 25751116
Drug: Community Treatment
Normalized name: ALCOHOL 80 mL in 100 mL TOPICAL LIQUID [Sanitizing Liquid for Community Support]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community Treatment by Experts
Study: 30948365
Drug: Sequential high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential high-dose chemotherapy (sHD) - 2 weekly 3-day blocks with cytarabine 2 g/m2 twice a day for 2 days plus idarubicin
Study: 30948365
Drug: Standard-intensity idarubicin-cytarabine-etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Standard-intensity idarubicin-cytarabine-etoposide (ICE) chemotherapy
Study: 30948365
Drug: Sequential high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential high-dose chemotherapy (sHD)
Study: 28166521
Drug: Tolvaptan (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolvaptan (daily split doses titrated to tolerance: 30/15, 45/15, 60/30, or 90/30 mg) for 12 months
Study: 21781648
Drug: Ibuprofen (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (800 mg taken orally thrice daily)
Study: 21781648
Drug: Oral Diclofenac
Normalized name: diclofenac Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Diclofenac (75 mg taken orally twice daily)
Study: 21781648
Drug: Diclofenac Epolamine
Normalized name: Diclofenac Epolamine
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac Epolamine Topical Patch (DETP, 1.3% applied topically twice daily)
Study: 21781648
Drug: Furosemide (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide (20 mg/2 min intravenously)
Study: 19041216
Drug: Midazolam (increasing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (increasing doses)
Study: 14646402
Drug: Tibolone (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibolone (2.5 mg once a day)
Study: 11605698
Drug: Colesevelam hydrochloride
Normalized name: Colesevelam Hydrochloride
DrugBank: Colesevelam (DB00930)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colesevelam hydrochloride (2.3 g/d, 3.0 g/d, 3.8 g/d, or 4.5 g/d)
Study: 7916039
Drug: Dacarbazine (DTIC)
Normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dacarbazine (DTIC) at 3,900 mg/m2 with cyclophosphamide (7.2 g/m2), carmustine (600 mg/m2), etoposide (2.4 g/m2)
Study: 7916039
Drug: Dacarbazine (DTIC)
Normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dacarbazine (DTIC) at 3,900 mg/m2 with CBV regimen
Study: 1590872
Drug: Prostaglandin E2
Normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prostaglandin E2 gel (1 mg intracervically)
Study: 27451978
Drug: Asparaginase (ASP)
Normalized name: Asparaginase
DrugBank: Asparaginase Erwinia chrysanthemi (DB08886)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Asparaginase (ASP) treatment
Study: 27451978
Drug: Permanent insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Permanent insulin therapy
Study: 25527735
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea (2 × 150 ml of 1% w/v tea/day)
Study: 16688105
Drug: Scaling and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scaling and root planing with Odontoson M irrigated with a 10% iodised solution
Study: 10390663
Drug: Droperidol (5-7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol (5-7.5 mg)
Study: 9014793
Drug: Transdermal glyceryl
Normalized name: glyceryl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal glyceryl trinitrate (10 mg per day)
Study: 1569240
Drug: 90 mg
Normalized name: papain 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 mg ketorolac
Study: 1569240
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg meperidine
Study: 1569240
Drug: ketorolac (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: ketorolac (30 mg or 90 mg)
Study: 6488765
Drug: 7 proprietary
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 proprietary corticosteroid creams
Study: 19352055
Drug: Multi-daily insulin
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-daily insulin injections therapy (MDI)
Study: 16144857
Drug: Heparin (HDhep)
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Heparin (HDhep)
Study: 10632654
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg extended-release cisapride
Study: 10632654
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg immediate-release cisapride
Study: 8819499
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg of codeine plus placebo
Study: 8819499
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg of codeine plus 100 mg of quinidine
Study: 8819499
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of quinidine plus placebo
Study: 1576068
Drug: Buffered aspirin
Normalized name: Buffered Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Buffered aspirin 500 mg
Study: 1576068
Drug: Buffered aspirin
Normalized name: Buffered Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Buffered aspirin preparations
Study: 1576068
Drug: Aspirin esterase
Normalized name: cocaine esterase
DrugBank: COCAINE ESTERASE (RBP-8000) (DB19225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin esterase activity
Study: 2864935
Drug: Etilefrine pivalate
Normalized name: etilefrine
DrugBank: Etilefrine (DB08985)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etilefrine pivalate (20 mg, oral administration once daily for 2-6 months)
Study: 26325116
Drug: Psyllium fiber
Normalized name: Konsyl Daily Psyllium Fiber
DrugBank: Plantago seed (DB11097)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psyllium fiber (3.5 g/day)
Study: 24901040
Drug: Spinal anesthesia
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal anesthesia (15 mg bupivacaine injected at L3-4)
Study: 22910171
Drug: Oseltamivir-zanamivir combination
Normalized name: Zanamivir
DrugBank: Zanamivir (DB00558)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oseltamivir-zanamivir combination therapy
Study: 22910171
Drug: Zanamivir monotherapy
Normalized name: Zanamivir
DrugBank: Zanamivir (DB00558)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zanamivir monotherapy
Study: 17284743
Drug: Labeled heme
Normalized name: Heme arginate
DrugBank: Heme arginate (DB17310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labeled heme iron (2 mg as hemoglobin)
Study: 17284743
Drug: Labeled heme
Normalized name: Heme arginate
DrugBank: Heme arginate (DB17310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labeled heme iron (4 mg as hemoglobin)
Study: 17284743
Drug: Labeled heme
Normalized name: Heme arginate
DrugBank: Heme arginate (DB17310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labeled heme iron (8 mg as hemoglobin)
Study: 17284743
Drug: Zinc intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc intake (1 mg)
Study: 17284743
Drug: Zinc intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc intake (9 mg)
Study: 7741186
Drug: Budesonide (Pulmicort;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (Pulmicort; 200 micrograms twice daily)
Study: 7741186
Drug: Long-acting theophylline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting theophylline (Theodur; 200 mg twice daily)
Study: 7741186
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Budesonide + Theophylline)
Study: 7741186
Drug: Budesonide and
Normalized name: Budesonide and formoterol only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide and Combination therapy
Study: 7234840
Drug: Cimetidine and
Normalized name: Cimetidine and sodium alginate only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine and Antacids (for isolated antral ulcer)
Study: 7234840
Drug: Antacids (for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacids (for primary duodenal ulcer)
Study: 7234840
Drug: Secondary ulcer
Normalized name: Secondary potassium phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secondary ulcer treatment
Study: 19685114
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg bupivacaine plus 25 microg fentanyl (group BF)
Study: 11532560
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of signs
Study: 9364289
Drug: gamma-linolenic acid
Normalized name: gamma-linolenic acid
DrugBank: Gamolenic acid (DB13854)
Approvals — FDA: no, EMA: no, PMDA: no
Description: gamma-linolenic acid (C18:3 n‐6) at a dosage of 274 mg twice a day
Study: 3296962
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g carbohydrate supplement
Study: 3296962
Drug: No carbohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: No carbohydrate supplement (control group)
Study: 3296962
Drug: Twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily insulin
Study: 3296962
Drug: Glycosylated haemoglobin
Normalized name: Glycosylated haemoglobin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycosylated haemoglobin concentration in children on twice daily insulin with nocturnal hypoglycaemia
Study: 25764960
Drug: Cost per
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cost per DFU treatment for ECM
Study: 25764960
Drug: Cost per
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cost per DFU treatment for HFDS
Study: 25764960
Drug: Total treatment
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total treatment costs comparison
Study: 8906009
Drug: Yuzpe regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yuzpe regimen (0.5 mg levonorgestrel and 0.1 mg ethinylestradiol)
Study: 8906009
Drug: Danazol (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danazol (600 mg orally, repeated after 12 hours)
Study: 1925837
Drug: Prazosin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin (2 mg, increased to 4, 10, and 20 mg)
Study: 1925837
Drug: Enalapril (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (5 mg, increased to 10, 20, and 40 mg)
Study: 6626435
Drug: Dipyridamole (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyridamole (2 or 20 micrograms/ml) in vitro
Study: 30558054
Drug: Change in
Normalized name: monofluorophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Change in CAP after treatment
Study: 27651323
Drug: Erdosteine (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erdosteine (600 mg/day)
Study: 24156617
Drug: 20 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 μg ethinyl estradiol (EE) and 100 μg levonorgestrel (LNG) OCs
Study: 24156617
Drug: 30 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 μg EE and 150 μg LNG OCs
Study: 18841784
Drug: Teacher tablets
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Teacher tablets for 7 days
Study: 18841784
Drug: Qinlian capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qinlian capsule for 7 days
Study: 10503854
Drug: High volume
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High volume hydration (16-17 mL/kg)
Study: 10503854
Drug: Low volume
Normalized name: CONNECTOR,LOW VOLUME,ENFIT MOOG INFINITY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low volume hydration (1-2 mL/kg)
Study: 8983875
Drug: Amino acids
Normalized name: Amino acids
DrugBank: Amino acids (DB09393)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acids infusion
Study: 1901635
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of angiotensin II (AII)
Study: 1901635
Drug: AII infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AII infusion
Study: 6292013
Drug: Naloxone (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (0.4 mg/min) infusion for 5 minutes before and 20 minutes after intravenous glucose (0.5 g/kg body weight)
Study: 31944628
Drug: SZC 5
Normalized name: Sildenafil citrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: SZC 5 g once-daily during maintenance phase (MP)
Study: 31944628
Drug: SZC 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: SZC 10 g once-daily during maintenance phase (MP)
Study: 28753179
Drug: Weekly intervention
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly intervention (10 sessions during 10 weeks) for MC group.
Study: 28753179
Drug: Both therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both therapy protocols (operant conditioning and systematic desensitization).
Study: 16215308
Drug: Diethylstilboestrol (DES)
Normalized name: Diethylstilbestrol
DrugBank: Diethylstilbestrol (DB00255)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diethylstilboestrol (DES) 1 mg/day with 75 mg of aspirin
Study: 11498451
Drug: Raloxifene (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene (60 mg daily for 1 month)
Study: 9778008
Drug: Deep cervical
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep cervical plexus block with 20 ml bupivacaine, 0.375%